In-Vitro Study of Dipyridamole–Propranolol Interaction in Protein Binding in the Absence and Presence of Nicotine Dipyridamole-propranolol interaction
Iranian Journal of Pharmaceutical Sciences,
Vol. 1 No. 3 (2005),
1 July 2005
,
Page 171-176
https://doi.org/10.22037/ijps.v1.39509
Abstract
The binding of drugs by plasma proteins is an important phenomenon, because it influences the size of the free fraction of the drugs in plasma. In this study the influence of dipyridamole (DP) on the protein binding of propranolol (PL) and PL on the protein binding of DP were studied alone and in the presence of nicotine (NC). The equilibrium dialysis was employed for protein binding studies. Results showed that DP (10 μg/ml) increased the protein binding of PL (1-40 μg/ml) by 4.1%, and PL(30 μg/ml) decreased the protein binding of DP (1-30 μg/ml) by 3.7%. NC (2 μg/ml) did not have any influence on the protein binding of PL and DP. Therefore, coadministration of PL and DP may cause an alteration in their pharmacological effects, but cigarette smoking possibly does not change protein binding of PL and DP.
- Dipyridamole
- Interaction
- Nicotine
- Propranolol
- Protein binding
How to Cite
References
[2] Sager G, Odd G, Jacobsen N, Jacobsen S. Variable binding of propranolol in human serum. Biochem Pharmacol 1979; 28: 905-11.
[3] Krishnia R, William GT, Richard E M. Assay of total and free propranolol in plasma by liquid chromatography with flourometric detection. Clin Chem 1985; 31: 131-4.
[4] Frans M, Bel P, Rene A, Breackman G, Marc GB. Binding of oxprenolol and propranolol to serum albumin and a-acidglycoprotein in man and other species. Biochem Pharmacol 1984; 33: 2065-9.
[5] Wood AJ, Feely J. Pharmacokinetic drug interaction with propranolol. Clin Pharmacol 1983; 8: 253-62.
[6] Uma T, Manju B, Sen P, Mahjan P. In vitro interaction between aspirin and propranolol at the plasma protein binding sites. Indian J Med Res 1987; 86: 95-100.
[7] Curtin NJ, Newel DR, Harris AL. Modulation of dipyridamole action by a-acid glycoprotein. Biochem Pharmacol 1989; 38: 3281-8.
[8] Macgregor TR, Sardi ED. In vitro protein binding behavior of dipyridamole. J Pharm Sci 1991; 80: 119-20.
[9] Curtin NJ, Bowman KJ, Turner RN, Huang B, Loughlin PJ, Calvert AH, Golding BT, Griffin RJ, Newell DR. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1- acid glycoprotein binding. British J Cancer 1999; 80: 1738-46.
[10] Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999; 36: 425-38.
[11] Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacol 1990; 9: 125-35.
[12] Shand DG, Nuckolls EM, Oates JA. Plasma propranolol levels in adults with observation in four children. Clin Pharmacol Ther 1970; 11: 112-20.
[13] Steyn JM. HPLC determination of dipyridamole in human serum. J Chromat 1979; 60: 934-43.
- Abstract Viewed: 249 times
- IJPS_Volume 1_Issue 3_Pages 171-176 Downloaded: 188 times